South Korea · Delayed Price · Currency is KRW Hanmi Pharm. Statistics
Total Valuation
Hanmi Pharm. has a market cap or net worth of KRW 6.14 trillion. The enterprise value is 6.33 trillion.
| Market Cap | 6.14T |
| Enterprise Value | 6.33T |
Important Dates
The last earnings date was Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Hanmi Pharm. has 12.69 million shares outstanding. The number of shares has increased by 0.11% in one year.
| Current Share Class | 12.69M |
| Shares Outstanding | 12.69M |
| Shares Change (YoY) | +0.11% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 17.69% |
| Float | 6.34M |
Valuation Ratios
The trailing PE ratio is 28.28 and the forward PE ratio is 28.56. Hanmi Pharm.'s PEG ratio is 2.36.
| PE Ratio | 28.28 |
| Forward PE | 28.56 |
| PS Ratio | 3.71 |
| PB Ratio | 3.86 |
| P/TBV Ratio | 4.59 |
| P/FCF Ratio | 28.35 |
| P/OCF Ratio | 22.48 |
| PEG Ratio | 2.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.84, with an EV/FCF ratio of 29.25.
| EV / Earnings | 29.16 |
| EV / Sales | 3.82 |
| EV / EBITDA | 16.84 |
| EV / EBIT | 22.91 |
| EV / FCF | 29.25 |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.26.
| Current Ratio | 1.82 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 1.11 |
| Debt / FCF | 1.93 |
| Interest Coverage | 19.25 |
Financial Efficiency
Return on equity (ROE) is 16.36% and return on invested capital (ROIC) is 14.17%.
| Return on Equity (ROE) | 16.36% |
| Return on Assets (ROA) | 8.04% |
| Return on Invested Capital (ROIC) | 14.17% |
| Return on Capital Employed (ROCE) | 16.26% |
| Weighted Average Cost of Capital (WACC) | 7.23% |
| Revenue Per Employee | 708.07M |
| Profits Per Employee | 92.83M |
| Employee Count | 2,338 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.90 |
Taxes
In the past 12 months, Hanmi Pharm. has paid 51.63 billion in taxes.
| Income Tax | 51.63B |
| Effective Tax Rate | 18.04% |
Stock Price Statistics
The stock price has increased by +10.14% in the last 52 weeks. The beta is 0.60, so Hanmi Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +10.14% |
| 50-Day Moving Average | 457,620.00 |
| 200-Day Moving Average | 464,455.00 |
| Relative Strength Index (RSI) | 63.95 |
| Average Volume (20 Days) | 134,773 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hanmi Pharm. had revenue of KRW 1.66 trillion and earned 217.04 billion in profits. Earnings per share was 17,099.34.
| Revenue | 1.66T |
| Gross Profit | 986.57B |
| Operating Income | 276.24B |
| Pretax Income | 286.27B |
| Net Income | 217.04B |
| EBITDA | 375.90B |
| EBIT | 276.24B |
| Earnings Per Share (EPS) | 17,099.34 |
Balance Sheet
The company has 409.31 billion in cash and 417.86 billion in debt, with a net cash position of -8.55 billion or -673.78 per share.
| Cash & Cash Equivalents | 409.31B |
| Total Debt | 417.86B |
| Net Cash | -8.55B |
| Net Cash Per Share | -673.78 |
| Equity (Book Value) | 1.59T |
| Book Value Per Share | 110,632.29 |
| Working Capital | 523.37B |
Cash Flow
In the last 12 months, operating cash flow was 272.90 billion and capital expenditures -56.52 billion, giving a free cash flow of 216.38 billion.
| Operating Cash Flow | 272.90B |
| Capital Expenditures | -56.52B |
| Depreciation & Amortization | 99.66B |
| Net Borrowing | -25.54B |
| Free Cash Flow | 216.38B |
| FCF Per Share | 17,052.23 |
Margins
Gross margin is 59.59%, with operating and profit margins of 16.69% and 13.11%.
| Gross Margin | 59.59% |
| Operating Margin | 16.69% |
| Pretax Margin | 17.29% |
| Profit Margin | 13.11% |
| EBITDA Margin | 22.71% |
| EBIT Margin | 16.69% |
| FCF Margin | 13.07% |
Dividends & Yields
This stock pays an annual dividend of 2,000.00, which amounts to a dividend yield of 0.41%.
| Dividend Per Share | 2,000.00 |
| Dividend Yield | 0.41% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 7 |
| Payout Ratio | 14.83% |
| FCF Payout Ratio | 11.73% |
| Buyback Yield | -0.11% |
| Shareholder Yield | 0.31% |
| Earnings Yield | 3.54% |
| FCF Yield | 3.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Hanmi Pharm. is 636,363.64, which is 31.62% higher than the current price. The consensus rating is "Buy".
| Price Target | 636,363.64 |
| Price Target Difference | 31.62% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 6.15% |
| EPS Growth Forecast (3Y) | 9.63% |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Hanmi Pharm. has an Altman Z-Score of 6.23 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.23 |
| Piotroski F-Score | 7 |